Delivery Order SPE2DB22D3301-SPE2DB25FZ0GM
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of HEMLIBRA 105 mg/0.7 mL vials totaling $6,168.26. This is a firm fixed-price delivery order with no set-aside designation, demonstrating competitive award authority. The order is scheduled for completion by August 29, 2025, with performance taking place at AmerisourceBergen's corporate facility in Conshohocken, Pennsylvania. HEMLIBRA is a specialty pharmaceutical product...
- The Defense Logistics Agency awarded a delivery order valued at $26,451.57 to AmerisourceBergen Drug Corp for the supply of HEMLIBRA 150 mg/ml vials. This firm fixed price contract, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a competitive award with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the pharmaceutical distributor maintains its...
- The Defense Logistics Agency awarded a $35,268.76 firm fixed price delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of HEMLIBRA 150 mg/ml vials. This non-competitive delivery order, with an ultimate completion date of June 3, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 master pharmaceutical supply vehicle running through December 2026. The performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,673.08 to AmerisourceBergen Drug Corp for the supply of HEMLIBRA 105 mg/0.7 ml vials. This is a firm fixed-price, non-set-aside contract with a completion date of August 8, 2025, and was awarded on July 18, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order operates under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $24,673.08 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Hemlibra 105 mg/0.7 ml vials. This is a firm fixed-price delivery order with a completion date of September 2, 2025, and will be performed at the vendor's location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating it was competitively awarded. Hemlibra is a specialty pharmaceutical product used in the treatment of hemophilia,...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $34,564.08 firm fixed-price delivery order is for the supply of HEMLIBRA 150 MG/ML VIALML, a critical medical product, with a period of performance through January 22, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,336.54 firm fixed-price delivery order contract is for the supply of HEMLIBRA 105 MG/0.7 ML VIAL 0.7ML, a specialty medication. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $33,409.40, is for the delivery of the specialty medication HEMLIBRA 150 MG/ML. The contract is a delivery order under a broader Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office division. The contract, valued at $23,330.40, is for the delivery of Hemlibra 105 mg/0.7 ml vials. Hemlibra is a specialty pharmaceutical product used to treat hemophilia. The contract has a period of performance through October 1, 2024 and is a firm-fixed-price delivery order. AmerisourceBergen, a major pharmaceutical distributor, has been awarded numerous federal...
- The Defense Logistics Agency awarded a delivery order valued at $7,613.15 to AmerisourceBergen Drug Corp on August 1, 2025, for 2,400 units of HUMATE-P VWF:RCOS with an ultimate completion date of August 22, 2025. This firm fixed-price, competitively awarded contract represents a non-set-aside delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0GMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HEMLIBRA 105 MG/0.7 ML vials, with a ceiling value of $6,168.26 under a firm fixed-price contract. The award was made on September 2, 2025, with an ultimate completion date of September 23, 2025. This non-set-aside delivery order represents a specific pharmaceutical procurement request fulfilled through the company's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement needs, particularly supporting military and veteran healthcare systems. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The IDC provides comprehensive pharmaceutical and medical supply support on a global basis to military healthcare programs, enabling the company to supply specialty medications, brand-name and generic drugs, vaccines, and other medical commodities across multiple therapeutic domains. The delivery order for HEMLIBRA, a specialty pharmaceutical product, exemplifies the company's role as a primary vendor within DLA's extensive medical supply chain supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 9/2/25 |